333
Views
6
CrossRef citations to date
0
Altmetric
Case Reports

A case of levetiracetam induced bullous pemphigoid

, , , , &
Pages 176-178 | Received 14 Jul 2012, Accepted 24 Aug 2012, Published online: 03 Oct 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Zhan-Miao Yi, 1–3, Cheng Wen, Ting Cai, Lu Xu, Xu-Li Zhong, Si-Yan Zhan & Suo-Di Zhai. (2019) Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles. Neuropsychiatric Disease and Treatment 15, pages 1-19.
Read now

Articles from other publishers (5)

Fatma Zgolli, Imen Aouinti, Ons Charfi, Widd Kaabi, Imen Hamza, Riadh Daghfous, Sarrah Kastalli, Ghozlane Lakhoua & Sihem El Aidli. (2023) Cutaneous adverse effects of antiepileptic drugs. Therapies.
Crossref
Luis E. IV Santaliz-Ruiz, Manuel E. Blanco-Cintron, Andrea P. Caro-Muñiz, Jaime Villa & Rafael F. Martin-Garcia. (2022) Levetiracetam-induced bullous pemphigoid in a young adult woman. JAAD Case Reports 21, pages 56-58.
Crossref
Xin-Xing Jin, Xue Wang, Ying Shan, Si-Zhe Li, Qun Xu, Hong-Zhong Jin & Ya-Gang Zuo. (2021) Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis. Archives of Dermatological Research 314:2, pages 191-201.
Crossref
Brian Spoelhof, Lynn Frendak & Lucia Rivera Lara. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 85 106 .
. (2013) Levetiracetam. Reactions Weekly 1434:1, pages 41-41.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.